SELLAS Life Sciences Group Sees Unusually High Options Volume (NASDAQ:SLS)

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) was the target of unusually large options trading activity on Monday. Traders bought 9,455 call options on the stock. This represents an increase of 146% compared to the typical daily volume of 3,838 call options.

Institutional Trading of SELLAS Life Sciences Group

Institutional investors and hedge funds have recently bought and sold shares of the stock. Anson Funds Management LP acquired a new position in shares of SELLAS Life Sciences Group in the 3rd quarter worth approximately $992,000. Geode Capital Management LLC lifted its holdings in SELLAS Life Sciences Group by 17.1% in the third quarter. Geode Capital Management LLC now owns 605,191 shares of the company's stock valued at $757,000 after buying an additional 88,183 shares during the period. XTX Topco Ltd bought a new stake in SELLAS Life Sciences Group during the third quarter valued at $78,000. State Street Corp grew its holdings in SELLAS Life Sciences Group by 30.2% during the 3rd quarter. State Street Corp now owns 174,529 shares of the company's stock worth $218,000 after acquiring an additional 40,500 shares during the period. Finally, Renaissance Technologies LLC acquired a new stake in SELLAS Life Sciences Group during the 2nd quarter worth about $39,000. 17.38% of the stock is currently owned by institutional investors and hedge funds.

SELLAS Life Sciences Group Stock Down 2.8 %

NASDAQ SLS traded down $0.04 on Friday, hitting $1.37. The company's stock had a trading volume of 1,950,638 shares, compared to its average volume of 4,661,264. The company's 50-day moving average is $1.08 and its 200 day moving average is $1.18. The firm has a market cap of $96.42 million, a PE ratio of -1.99 and a beta of 2.42. SELLAS Life Sciences Group has a 1-year low of $0.66 and a 1-year high of $1.84.

Remove Ads

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.